Sealonix, Inc. Closes $20 Million Financing to Develop Sealant Products for Abdominopelvic and Orthopedic Procedures
Summary
The initial product that Sealonix is developing is a sealant patch providing rapid hemostasis for abdominopelvic and orthopedic procedures. Dr. William Spotnitz, Professor of Surgery at the University of Virginia Health System with over 20 years in hemostat device research, noted, "Obtaining hemostasis with existing approved devices during surgical procedures can be a challenging and time-consuming task. The PramStat patch has the potential to drastically reduce this time as well as instill confidence in the durability of the hemostatic seal." Amar Sawhney, Sealonix CEO, commented, "The PramStat patch builds on many years of research done by this experienced team, and now will move rapidly into clinical development. Excelestar Ventures generally invests in a strong team leading a B2B company, either in tech or medical devices, that has a clear, disruptive technology.